<DOC>
	<DOCNO>NCT00576563</DOCNO>
	<brief_summary>To investigate evolution 18F-deoxyglucose ( FDG ) uptake tumour characteristic determine plasma patient rectal cancer radiotherapy combine radiotherapy chemotherapy . The change FDG uptake primary tumour evolution key tumour characteristic radiotherapy alone combination chemotherapy predictive pathological tumour response . Study hypothesis The change FDG uptake primary tumour evolution key tumour characteristic radiotherapy alone combination chemotherapy predictive pathological tumour response .</brief_summary>
	<brief_title>Rectal Study : Value Repeated FDG-PET-CT Scans Rectal Cancer</brief_title>
	<detailed_description>This translational research part aim give insight way radiation injury tumour response develop . It involve three part : 1 . Repetitive FDG-PET-CT scan order assess early tumour response monitoring . 2 . Blood sampling , radiotherapy order find predictor normal tissue injury tumour response . 3 . Extra stain tumour biopsy . 1 . FDG-PET-CT scan The FDG-PET-CT scan i.v . contrast give information tumour metabolism morphology . The pre-treatment max SUV prognostic high value confers bad prognosis . Our group show vitro vivo high FDG uptake due tumour hypoxia . The evolution max SUV radiotherapy may thus predictive ultimate tumour response . Therefore , two extra FDG-PET-CT scan do radiotherapy group patient receive long-term radiochemotherapy : one day 7 one day 14 . This enable calculation max SUV kinetics treatment . Tumour response determine FDG-PET-CT scan 3-5 day short- course radiotherapy 6-8 week long- term radiochemotherapy . 2 Blood sample Blood collection processing , radiotherapy do accord serum protocol . For perform ELISA 's blood sample collect put freezer . The analysis blood material perform month year collection re-analysis regard describe protein group may necessary depend outcome . 1 . Before radiotherapy , 10 millilitre blood take . 2 . At day 7 , day 14 6-8 week end radiotherapy long- term radiotherapy 3-5 day short - course radiotherapy , i.e . day FDG-PET-CT scan perform , 10 millilitre serum ( EDTA tube ) take investigate evolution protein treatment , kinetics may important predictive factor . 3 Extra stain tumour biopsy The tumour biopsy may stain marker proliferation ( e.g . KI 67 ) , apoptosis ( e.g . M30 ) , hypoxia ( e.g . HIF , CA 9 , Glut 1 3 ) others ( e.g . EGFR EGFRvIII ) , order correlate measurement response .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Histological proven rectal cancer UICC stage IIV WHO performance status 02 Less 10 % weight loss last 6 month In case previous chemotherapy , radiotherapy start minimum 21 day last chemotherapy course No recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) Life expectancy 6 month Measurable cancer Willing able comply study prescription 18 year old Not pregnant willing take adequate contraceptive measure study Have give write informed consent patient registration No previous radiotherapy pelvis Not adenocarcinoma histology History prior pelvis radiotherapy Recent ( &lt; 3 month ) myocardial infarction Uncontrolled infectious disease Less 18 year old Pregnant willing take adequate contraceptive measure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>rectal cancer</keyword>
	<keyword>blood protein</keyword>
	<keyword>irradiation</keyword>
	<keyword>FDG-PET-CT</keyword>
</DOC>